InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,481.43
(
0.31%
)
US TECH 100
19,116.00
(
-0.47%
)
Dow Jones
39,506.66
(
0.91%
)
Brent Oil
85.21
(
1.41%
)
Bitcoin
60,882.94
(
-3.61%
)
Post# of 252317
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

oc631

Send PM Follow Ignore
Followers 15
Posts 1749
Boards Moderated 0
Alias Born 08/12/2007

oc631

Re: genisi post# 117537

Monday, 04/04/2011 10:07:22 AM

Monday, April 04, 2011 10:07:22 AM

Post# of 252317

EASL - first SVR data for mericitabine (a.k.a RG7128 ) interim analysis from the Jump-C phase 2b study. Note the high relapse rate





Surprising to see such a high rate in combination with SOC. Do you think Roche will move forward with the PROPEL study? How about INFORM? I am obviously biased towards the nuke class but to me Jump-C just argues for VRUS' strategy going forward.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up